Truist Financial’s Protara Therapeutics TARA Stock Holding History

Truist Financial’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$313K	Buy	60,000 +20,000	+50%	+$118K	﹤0.01%	2361
2025 Q4	$213K	Hold	40,000	–	–	﹤0.01%	2570
2025 Q3	$174K	Hold	40,000	–	–	﹤0.01%	2576
2025 Q2	$121K	Hold	40,000	–	–	﹤0.01%	2483
2025 Q1	$170K	Hold	40,000	–	–	﹤0.01%	2393
2024 Q4	$211K	Hold	40,000	–	–	﹤0.01%	2365
2024 Q3	$73.2K	Buy	40,000 +20,000	+100%	+$41.1K	﹤0.01%	2440
2024 Q2	$41.6K	Hold	20,000	–	–	﹤0.01%	2613
2024 Q1	$80.2K	Buy	+20,000	New	+$64.5K	﹤0.01%	2563

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Truist Financial's TARA Position: Q1 2026 in Review

Truist Financial increased its Protara Therapeutics (TARA) stake by 50% in Q1 2026, buying an estimated $118K and bringing the position to 60,000 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #2361.

Truist Financial first reported a position in TARA in Q1 2024 and has held it in 9 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

Truist Financial held 60,000 shares of Protara Therapeutics worth $313K as of Q1 2026.
Truist Financial bought 20,000 Protara Therapeutics shares in Q1 2026, an estimated $118K.
Protara Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #2361 holding.
Truist Financial first reported a position in Protara Therapeutics in Q1 2024 and has held it in 9 quarters since.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.